FOXA1 Overexpression Mediates Endocrine Resistance by Altering The
FOXA1 overexpression mediates endocrine resistance PNAS PLUS by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer Xiaoyong Fua,b,c, Rinath Jeselsohnd, Resel Pereiraa,b,c, Emporia F. Hollingsworthe, Chad J. Creightonb,f, Fugen Lid, Martin Sheaa,b,f, Agostina Nardonea,b,f, Carmine De Angelisa,b,f, Laura M. Heiserg, Pavana Anurh, Nicholas Wangg, Catherine S. Grassog, Paul T. Spellmanh, Obi L. Griffithi, Anna Tsimelzona,b,f, Carolina Gutierreze, Shixia Huangb,c, Dean P. Edwardsb,c,e, Meghana V. Trivedia,b,j,k, Mothaffar F. Rimawia,b,f, Dolores Lopez-Terradae, Susan G. Hilsenbecka,b,f, Joe W. Grayg, Myles Brownd, C. Kent Osbornea,b,c,f, and Rachel Schiffa,b,c,f,1 aLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030; bDan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030; cDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; dDana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02215; eDepartment of Pathology, Baylor College of Medicine, Houston, TX 77030; fDepartment of Medicine, Baylor College of Medicine, Houston, TX 77030; gDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239; hDepartment of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239; iMcDonnell Genome Institute, Washington University, St. Louis, MO 63108; jDepartment of Pharmacy Practice and Translational Research, University of Houston, Houston, TX 77204; and kDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204 Edited by Bert W. O’Malley, Baylor College of Medicine, Houston, TX, and approved August 26, 2016 (received for review May 18, 2016) Forkhead box protein A1 (FOXA1) is a pioneer factor of estrogen renders these genomic regions more accessible to other tran- receptor α (ER)–chromatin binding and function, yet its aberration scription factors, such as ER (9), progesterone receptor (PR) in endocrine-resistant (Endo-R) breast cancer is unknown.
[Show full text]